Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Accounts Payables (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Accounts Payables data on record, last reported at $3.7 million in Q1 2026.

  • On a quarterly basis, Accounts Payables rose 2362.91% to $3.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.7 million, a 2362.91% increase, with the full-year FY2025 number at $9.3 million, up 107.47% from a year prior.
  • Accounts Payables reached $3.7 million in Q1 2026 per OLMA's latest filing, down from $9.3 million in the prior quarter.
  • Over the last five years, Accounts Payables for OLMA hit a ceiling of $9.3 million in Q4 2025 and a floor of $14000.0 in Q3 2022.
  • A 5-year average of $2.6 million and a median of $2.2 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: surged 15664.29% in 2023, then tumbled 98.03% in 2025.
  • Tracing OLMA's Accounts Payables over 5 years: stood at $374000.0 in 2022, then skyrocketed by 621.39% to $2.7 million in 2023, then skyrocketed by 65.31% to $4.5 million in 2024, then soared by 107.47% to $9.3 million in 2025, then tumbled by 59.81% to $3.7 million in 2026.
  • Business Quant data shows Accounts Payables for OLMA at $3.7 million in Q1 2026, $9.3 million in Q4 2025, and $3.5 million in Q3 2025.